LCTX vs. SPMO

Last updated Apr 2, 2026

Compare and contrast key facts about Lineage Cell Therapeutics, Inc. (LCTX) and Invesco S&P 500 Momentum ETF (SPMO).

SPMO is a passively managed fund by Invesco that tracks the performance of the S&P 500 Momentum Index. It was launched on Oct 9, 2015.

Performance

LCTX vs. SPMO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Lineage Cell Therapeutics, Inc. (LCTX) and Invesco S&P 500 Momentum ETF (SPMO). The values are adjusted to include any dividend payments, if applicable.

LCTX vs. SPMO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
LCTX Lineage Cell Therapeutics, Inc.	-4.79%	232.34%	-53.90%	-6.84%	-52.24%	39.20%	97.75%	-2.52%	-51.46%	-40.44%
SPMO Invesco S&P 500 Momentum ETF	-3.77%	26.58%	45.82%	17.56%	-10.45%	22.64%	28.25%	25.93%	-0.92%	27.76%

Returns By Period

In the year-to-date period, LCTX achieves a -4.79% return, which is significantly lower than SPMO's -3.77% return. Over the past 10 years, LCTX has underperformed SPMO with an annualized return of -4.63%, while SPMO has yielded a comparatively higher 17.41% annualized return.

LCTX

• 1D: 0.63%
• 1M: -18.46%
• YTD: -4.79%
• 6M: -5.92%
• 1Y: 286.86%
• 3Y*: 1.96%
• 5Y*: -8.36%
• 10Y*: -4.63%

SPMO

• 1D: 2.13%
• 1M: -4.40%
• YTD: -3.77%
• 6M: -4.53%
• 1Y: 23.97%
• 3Y*: 29.27%
• 5Y*: 17.66%
• 10Y*: 17.41%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

LCTX vs. SPMO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LCTX

LCTX Risk / Return Rank: 96
LCTX Sharpe Ratio Rank: 98
LCTX Sortino Ratio Rank: 97
LCTX Omega Ratio Rank: 92
LCTX Calmar Ratio Rank: 98
LCTX Martin Ratio Rank: 97

SPMO

SPMO Risk / Return Rank: 64
SPMO Sharpe Ratio Rank: 57
SPMO Sortino Ratio Rank: 60
SPMO Omega Ratio Rank: 63
SPMO Calmar Ratio Rank: 73
SPMO Martin Ratio Rank: 66

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LCTX vs. SPMO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Lineage Cell Therapeutics, Inc. (LCTX) and Invesco S&P 500 Momentum ETF (SPMO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	LCTX	SPMO	Difference
Sharpe ratio Return per unit of total volatility	3.78	1.06	+2.72
Sortino ratio Return per unit of downside risk	3.99	1.60	+2.39
Omega ratio Gain probability vs. loss probability	1.43	1.24	+0.19
Calmar ratio Return relative to maximum drawdown	9.69	1.96	+7.73
Martin ratio Return relative to average drawdown	23.47	6.90	+16.57
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

LCTX vs. SPMO - Sharpe Ratio Comparison

The current LCTX Sharpe Ratio is 3.78, which is higher than the SPMO Sharpe Ratio of 1.06. The chart below compares the historical Sharpe Ratios of LCTX and SPMO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	LCTX	SPMO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.78	1.06	+2.72
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.12	0.93	-1.05
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.06	0.87	-0.93
Sharpe Ratio (All Time) Calculated using the full available price history	-0.02	0.86	-0.88

Correlation

The correlation between LCTX and SPMO is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

LCTX vs. SPMO - Dividend Comparison

LCTX has not paid dividends to shareholders, while SPMO's dividend yield for the trailing twelve months is around 0.89%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
LCTX Lineage Cell Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	8.66%	0.00%
SPMO Invesco S&P 500 Momentum ETF	0.89%	0.73%	0.48%	1.63%	1.66%	0.52%	1.27%	1.39%	1.05%	0.77%	1.94%	0.36%

Drawdowns

LCTX vs. SPMO - Drawdown Comparison

The maximum LCTX drawdown since its inception was -99.31%, which is greater than SPMO's maximum drawdown of -30.95%. Use the drawdown chart below to compare losses from any high point for LCTX and SPMO.

Drawdown Indicators

	LCTX	SPMO	Difference
Max Drawdown Largest peak-to-trough decline	-99.31%	-30.95%	-68.36%
Max Drawdown (1Y) Largest decline over 1 year	-26.02%	-12.70%	-13.32%
Max Drawdown (5Y) Largest decline over 5 years	-87.13%	-22.74%	-64.39%
Max Drawdown (10Y) Largest decline over 10 years	-88.88%	-30.95%	-57.93%
Current Drawdown Current decline from peak	-91.86%	-7.31%	-84.55%
Average Drawdown Average peak-to-trough decline	-78.63%	-4.66%	-73.97%
Ulcer Index Depth and duration of drawdowns from previous peaks	10.74%	3.60%	+7.14%

Volatility

LCTX vs. SPMO - Volatility Comparison

Lineage Cell Therapeutics, Inc. (LCTX) has a higher volatility of 18.38% compared to Invesco S&P 500 Momentum ETF (SPMO) at 7.22%. This indicates that LCTX's price experiences larger fluctuations and is considered to be riskier than SPMO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	LCTX	SPMO	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.38%	7.22%	+11.16%
Volatility (6M) Calculated over the trailing 6-month period	42.01%	12.80%	+29.21%
Volatility (1Y) Calculated over the trailing 1-year period	77.07%	22.77%	+54.30%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	72.72%	19.08%	+53.64%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	75.29%	20.09%	+55.20%